Literature DB >> 2370682

Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane.

S S Rhee1, H X Hui, E Hunter.   

Abstract

The capsids of Mason-Pfizer monkey virus (M-PMV), an immunosuppressive type D retrovirus, are preassembled in the infected cell cytoplasm and are then transported to the plasma membrane, where they are enveloped in a virus glycoprotein-containing lipid bilayer. The role of viral glycoprotein in intracellular transport of M-PMV capsids was investigated with a spontaneous mutant (5A) of M-PMV, which we show here to be defective in envelope glycoprotein biosynthesis. DNA sequence analysis of the env gene of mutant 5A reveals a single nucleotide deletion in the middle of the gene, which results in the synthesis of a truncated form of the envelope glycoprotein. Evidence is presented showing that the mutant glycoprotein is not expressed at the cell surface but is retained in the endoplasmic reticulum. Normal levels of gag-pro-pol precursor polyproteins are made and processed in mutant genome-transfected cells, and high levels of noninfectious particles lacking viral glycoprotein are released with normal kinetics into the culture medium. No intracisternal budding of capsids is observed. We conclude that viral glycoprotein is required neither for targeting preassembled capsids of M-PMV to the plasma membrane for final maturation nor for the budding process. Since the presence or absence of M-PMV glycoprotein at the site of budding does not affect the efficiency or kinetics of the targeting process, the preassembled capsid of M-PMV, in contrast to those of intracisternal type A particles, appears to have an intrinsic signal for intracellular transport to the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2370682      PMCID: PMC249680     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  Intracellular aspects of the process of protein synthesis.

Authors:  G Palade
Journal:  Science       Date:  1975-08-01       Impact factor: 47.728

2.  Temporal relationship of translation and glycosylation of immunoglobulin heavy and light chains.

Authors:  L W Bergman; W M Kuehl
Journal:  Biochemistry       Date:  1978-11-28       Impact factor: 3.162

3.  Inhibition of Rous sarcoma virus replication by 2-deoxyglucose and tunicamycin: identification of an unglycosylated env gene product.

Authors:  R Stohrer; E Hunter
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

4.  Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events.

Authors:  A M Schultz; A Rein
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

6.  Effects of glucosamine, 2-deoxyglucose, and tunicamycin on glycosylation, sulfation, and assembly of influenza viral proteins.

Authors:  K Nakamura; R W Compans
Journal:  Virology       Date:  1978-02       Impact factor: 3.616

7.  Purification and properties of an endo-beta-N-acetylglucosaminidase from Streptomyces griseus.

Authors:  A L Tarentino; F Maley
Journal:  J Biol Chem       Date:  1974-02-10       Impact factor: 5.157

8.  Responses of infant rhesus monkeys to inoculation with Mason-Pfizer monkey virus materials.

Authors:  D L Fine; J C Landon; R J Pienta; M T Kubicek; M G Valerio; W F Loeb; H C Chopra
Journal:  J Natl Cancer Inst       Date:  1975-03       Impact factor: 13.506

9.  An improved technique for obtaining enhanced infectivity with herpes simplex virus type 1 DNA.

Authors:  N D Stow; N M Wilkie
Journal:  J Gen Virol       Date:  1976-12       Impact factor: 3.891

10.  Suppression of glycoprotein formation of Semliki Forest, influenza, and avian sarcoma virus by tunicamycin.

Authors:  R T Schwarz; J M Rohrschneider; M F Schmidt
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

View more
  48 in total

1.  Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro.

Authors:  S D Parker; E Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

2.  The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process.

Authors:  M Tritel; M D Resh
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Variable sensitivity to substitutions in the N-terminal heptad repeat of Mason-Pfizer monkey virus transmembrane protein.

Authors:  Chisu Song; Eric Hunter
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

4.  Protection of macaques against infection with simian type D retrovirus (SRV-1) by immunization with recombinant vaccinia virus expressing the envelope glycoproteins of either SRV-1 or Mason-Pfizer monkey virus (SRV-3).

Authors:  B A Brody; E Hunter; J D Kluge; R Lasarow; M Gardner; P A Marx
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly.

Authors:  S S Rhee; E Hunter
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Authors:  X Yu; X Yuan; Z Matsuda; T H Lee; M Essex
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

8.  In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein modulates virus release.

Authors:  P Liljeström; S Lusa; D Huylebroeck; H Garoff
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

9.  Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus.

Authors:  M Suomalainen; H Garoff
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 Nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4.

Authors:  S S Rhee; J W Marsh
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.